Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066804 · ClinicalTrials.gov registry record · Phase 3
A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,572
- Enrollment target
NCT03066804: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT03066804 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,572 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (233% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03066804, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,572 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction (HFpEF).
Primary Outcome
To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF
Interventions
- DRUG Valsartan
- DRUG sacubitril/valsartan
- DRUG Enalapril
- DRUG Placebo to match sacubitril/valsartan
- DRUG Placebo to match enalapril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,572 participants |
| Start Date | 2017-08-22 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 3 |
What the finished NCT03066804 record still lists
NCT03066804 is an interventional study that assigns participants to a tested intervention. Its 2,572 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (233% higher).
The record links to 0 conditions, and to 5 interventions - of which Valsartan is the first listed.
NCT03066804 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03066804 about?
NCT03066804 is a clinical study titled "A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients". The purpose of this study is to demonstrate the superiority of LCZ696 over individualized medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure with preserved ejection fraction...
What is the current status of trial NCT03066804?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,572 participants. The study started on 2017-08-22. Estimated completion is 2019-10-28.
What interventions are being tested in trial NCT03066804?
The interventions under investigation include: Valsartan (DRUG), sacubitril/valsartan (DRUG), Enalapril (DRUG), Placebo to match sacubitril/valsartan (DRUG), Placebo to match enalapril (DRUG).
Who is sponsoring clinical trial NCT03066804?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03066804's enrollment target sits among peer trials
2,572 85th of 2000 higher than 1,916 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI